Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Predictors of SARS-CoV-2 infection following high-risk exposure

Kristin L. Andrejko, Jake Pry, Jennifer F. Myers, John Openshaw, James Watt, Nozomi Birkett, Jennifer L. DeGuzman, Sophia S. Li, Camilla M. Barbaduomo, Anna T. Fang, Vivian H. Tran, Mahsa H. Javadi, Paulina M. Frost, Zheng N. Dong, Seema Jain, Joseph A. Lewnard on behalf of the California COVID-19 Case-Control Study Team
doi: https://doi.org/10.1101/2021.10.20.21265295
Kristin L. Andrejko
1Division of Epidemiology and Biostatistics, School of Public Health, University of California, Berkeley, California, United States
BS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jake Pry
2California Department of Public Health, Richmond, California, United States
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer F. Myers
2California Department of Public Health, Richmond, California, United States
MPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Openshaw
2California Department of Public Health, Richmond, California, United States
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Watt
2California Department of Public Health, Richmond, California, United States
MD, MPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nozomi Birkett
2California Department of Public Health, Richmond, California, United States
BS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer L. DeGuzman
2California Department of Public Health, Richmond, California, United States
MPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sophia S. Li
2California Department of Public Health, Richmond, California, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Camilla M. Barbaduomo
2California Department of Public Health, Richmond, California, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna T. Fang
2California Department of Public Health, Richmond, California, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vivian H. Tran
2California Department of Public Health, Richmond, California, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mahsa H. Javadi
2California Department of Public Health, Richmond, California, United States
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paulina M. Frost
2California Department of Public Health, Richmond, California, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zheng N. Dong
2California Department of Public Health, Richmond, California, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Seema Jain
2California Department of Public Health, Richmond, California, United States
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jlewnard@berkeley.edu Seema.Jain@cdph.ca.gov
Joseph A. Lewnard
1Division of Epidemiology and Biostatistics, School of Public Health, University of California, Berkeley, California, United States
3Division of Infectious Diseases & Vaccinology, School of Public Health, University of California, Berkeley, California, United States
4Center for Computational Biology, College of Engineering, University of California, Berkeley, California, United States
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jlewnard@berkeley.edu Seema.Jain@cdph.ca.gov
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background Non-pharmaceutical interventions (NPIs) are recommended for COVID-19 mitigation. However, the effectiveness of NPIs in preventing SARS-CoV-2 transmission remains poorly quantified.

Methods We conducted a test-negative design case-control study enrolling cases (testing positive for SARS-CoV-2) and controls (testing negative) with molecular SARS-CoV-2 diagnostic test results reported to California Department of Public Health between 24 February-26 September, 2021. We used conditional logistic regression to assess predictors of case status among participants who reported contact with an individual known or suspected to have been infected with SARS-CoV-2 (“high-risk exposure”) within ≤14 days of testing.

Results 643 of 1280 cases (50.2%) and 204 of 1263 controls (16.2%) reported high-risk exposures ≤14 days before testing. Adjusted odds of case status were 2.94-fold (95% confidence interval: 1.66-5.25) higher when high-risk exposures occurred with household members (vs. other contacts), 2.06-fold (1.03-4.21) higher when exposures occurred indoors (vs. not indoors), and 2.58-fold (1.50-4.49) higher when exposures lasted ≥3 hours (vs. shorter durations) among unvaccinated and partially-vaccinated individuals; excess risk associated with such exposures was mitigated among fully-vaccinated individuals. Mask usage by participants or their contacts during high-risk exposures reduced adjusted odds of case status by 48% (8-72%). Adjusted odds of case status were 68% (32-84%) and 77% (59-87%) lower for partially- and fully-vaccinated participants, respectively, than for unvaccinated participants. Benefits of mask usage were greatest when exposures lasted ≥3 hours, occurred indoors, or involved non-household contacts.

Conclusions NPIs reduced the likelihood of SARS-CoV-2 infection following high-risk exposure. Vaccine effectiveness was substantial for partially and fully vaccinated persons.

KEY POINTS

  • SARS-CoV-2 infection risk was greatest for unvaccinated participants when exposures to known or suspected cases occurred indoors or lasted ≥3 hours.

  • Face mask usage when participants were exposed to a known or suspect case reduced odds of infection by 48%.

Competing Interest Statement

JAL discloses receipt of grants and honoraria from Pfizer, Inc. unrelated to this work.

Funding Statement

The study was supported by the California Department of Public Health. JP, JO, and JFM were supported by a grant from the ELC program of the US CDC (program number 0187.0150). JAL was supported by NIH/NIAID (grant R01-AI14812701).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study protocol was granted a non-research determination by the State of California Health and Human Services Agency Committee for the Protection of Human Subjects (project number: 2021-034).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵§ Members of the California COVID-19 Case-Control Study Team are listed in the main text.

Data Availability

Direct data requests to the corresponding author at jlewnard{at}berkeley.edu

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted October 23, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Predictors of SARS-CoV-2 infection following high-risk exposure
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Predictors of SARS-CoV-2 infection following high-risk exposure
Kristin L. Andrejko, Jake Pry, Jennifer F. Myers, John Openshaw, James Watt, Nozomi Birkett, Jennifer L. DeGuzman, Sophia S. Li, Camilla M. Barbaduomo, Anna T. Fang, Vivian H. Tran, Mahsa H. Javadi, Paulina M. Frost, Zheng N. Dong, Seema Jain, Joseph A. Lewnard
medRxiv 2021.10.20.21265295; doi: https://doi.org/10.1101/2021.10.20.21265295
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Predictors of SARS-CoV-2 infection following high-risk exposure
Kristin L. Andrejko, Jake Pry, Jennifer F. Myers, John Openshaw, James Watt, Nozomi Birkett, Jennifer L. DeGuzman, Sophia S. Li, Camilla M. Barbaduomo, Anna T. Fang, Vivian H. Tran, Mahsa H. Javadi, Paulina M. Frost, Zheng N. Dong, Seema Jain, Joseph A. Lewnard
medRxiv 2021.10.20.21265295; doi: https://doi.org/10.1101/2021.10.20.21265295

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (280)
  • Allergy and Immunology (579)
  • Anesthesia (139)
  • Cardiovascular Medicine (1943)
  • Dentistry and Oral Medicine (252)
  • Dermatology (184)
  • Emergency Medicine (333)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (698)
  • Epidemiology (11098)
  • Forensic Medicine (8)
  • Gastroenterology (622)
  • Genetic and Genomic Medicine (3164)
  • Geriatric Medicine (308)
  • Health Economics (561)
  • Health Informatics (2042)
  • Health Policy (862)
  • Health Systems and Quality Improvement (782)
  • Hematology (310)
  • HIV/AIDS (682)
  • Infectious Diseases (except HIV/AIDS) (12714)
  • Intensive Care and Critical Care Medicine (707)
  • Medical Education (317)
  • Medical Ethics (92)
  • Nephrology (334)
  • Neurology (2981)
  • Nursing (164)
  • Nutrition (463)
  • Obstetrics and Gynecology (589)
  • Occupational and Environmental Health (614)
  • Oncology (1549)
  • Ophthalmology (476)
  • Orthopedics (185)
  • Otolaryngology (266)
  • Pain Medicine (202)
  • Palliative Medicine (57)
  • Pathology (402)
  • Pediatrics (912)
  • Pharmacology and Therapeutics (381)
  • Primary Care Research (355)
  • Psychiatry and Clinical Psychology (2782)
  • Public and Global Health (5588)
  • Radiology and Imaging (1092)
  • Rehabilitation Medicine and Physical Therapy (631)
  • Respiratory Medicine (759)
  • Rheumatology (338)
  • Sexual and Reproductive Health (311)
  • Sports Medicine (289)
  • Surgery (343)
  • Toxicology (48)
  • Transplantation (159)
  • Urology (132)